Manzo Pharmaceuticals, Inc.

Disclosure for quarter ending March 31, 2016

1) Name of the issuer and its predecessors (if any)

Manzo Pharmaceuticals, Inc.
Formerly, Fortune Oil & Gas, Inc.

2) Address of the issuer's principal executive offices

Company Headquarters Address 1: PO Box 107
Address 2: Milford
Address 3: PA 18337
Phone: 570-249-6000
Email: contactus@manzopharma.com
Website(s): www.manzopharma.com

IR Contact
Address 1: PO Box 107
Address 2: Milford
Address 3: PA 18337
Phone: 570-249-6000
Email: contactus@manzopharma.com
Website(s): www.manzopharma.com

3) Security Information

Trading Symbol: FOGC
Exact title and class of securities outstanding:
Common CUSIP: 349683102
Par or Stated Value: $0.001
Total shares authorized: 1,900,000,000 as of: 3/31/16
Total shares outstanding: 1,159,522,000 as of: 3/31/16

Transfer Agent
Name: Signature Stock Transfer, Inc.
Address 1: 2632 Coachlight Court
Address 2: Plano
Address 3: TX 75093
Phone: 972-612-4120
Is the Transfer Agent registered under the Exchange Act?* Yes: ■ No:
*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security: NONE

Describe any trading suspension orders issued by the SEC in the past 12 months. NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

4) Issuance History

For the three months ended March 31, 2016 - The following issuances have taken place:

5) Financial Statements

* See Financial Statements below

Manzo Pharmaceuticals, Inc.
Consolidated Balance Sheets
(Unaudited)

		March 31, 2016		December 31, 2015
ASSETS				
CURRENT ASSETS				
Cash and cash equivalents		$ 15,477		$ 12,311
Total Current Assets		15,477		12,311
Property, plant & equipment (Net)		-		-
Intangible assets (Net)		110,100		110,100
Goodwill		70,000		70,000
TOTAL ASSETS		$ 195,577		$ 192,411
LIABILITIES AND STOCKHOLDERS' DEFICIT				
CURRENT LIABILITIES				
Accounts payable and accrued expenses		$ -		$ -
Derivative liability		-		-
Notes Payable related party		-		-
Current portion of long-term debt net of discount		(8,405)		(11,094)
Total Current Liabilities		(8,405)		(11,094)
Total Liabilities		(8,405)		(11,094)
STOCKHOLDERS' DEFICIT				
Preferred Stock, par value $.001 per share, 5,000,000 shares authorized, 4,000,000 issued and outstanding at 3/31/2016 and 12/31/2015, respectively		444		444
Common stock, par value $0.001 per share, 1,900,000,000 shares authorized; 1,159,522,000 issued, and outstanding 3/31/2016 and 12/31/2015, respectively		1,159,522		1,159,522
Additional paid-in-capital		11,941,290		11,941,290
Retained Deficit		(12,897,274)		(12,897,751)
Total Stockholders' Deficit		203,982		203,505
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$ 195,577		$ 192,411

"The accompanying notes are an integral part of these financial statements"

Manzo Pharmaceuticals, Inc.
Consolidated Statements of Operations
(Unaudited)

	For The Three Months Ended 31-Mar 2016	2015
REVENUES	$ 2,325	$ 21
COST OF SALES	78	-
GROSS PROFIT	2,247	21
OPERATING EXPENSES		
Research and Development	-	-
General and administrative	6,750	10,606
OPERATING EXPENSES	6,750	10,606
LOSS FROM OPERATIONS	(4,503)	(10,585)
OTHER INCOME (EXPENSE)		
Impairment expense	-	-
Gain(loss) on derivatives	-	2,848
Interest expense	-	(22,746)
TOTAL OTHER INCOME (EXPENSE)	-	(19,898)
NET INCOME (LOSS) BEFORE INCOME TAXES	(4,503)	(30,483)
PROVISION FOR INCOME TAXES	-	-
NET INCOME (LOSS)	$ (4,503)	$ (30,483)
OTHER COMPREHENSIVE INCOME /(LOSS) NET OF TAXES		
Unrealized income (loss) on held for sale marketable securities	-	-
COMPREHENSIVE INCOME/(LOSS)	$ (4,503)	$ (30,483)
LOSS PER SHARE - BASIC & DILUTED	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	1,159,522,000	464,522,000

"The accompanying notes are an integral part of these financial statements"

Manzo Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(Unaudited)

	For The Three Months Ended March 31, 2016	For The Three Months Ended March 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Income(loss)	$ (4,503)	$ (30,483)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Debt accretion	-	22,746
Stock issued for services	-	
Derivative liabilities (gain)loss	-	(2,848)
Change in operating assets and liabilities, net of acquisition:		
Increase (decrease) in accounts payable and accrued expenses	-	-
Increase (decrease) in other current liabilities	-	-
Net Cash Used in Operating Activities	(4,503)	(10,585)
CASH FLOWS FROM INVESTING ACTIVITIES		
Net Cash provided by (used in) Investing Activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Cash paid to related party loans	(7,331)	-
Cash received from related party loans	15,000	10,000
Net Cash Provided by (Used in) Financing Activities	7,669	10,000
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	3,166	(585)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	12,311	10,687
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 15,477	$ 10,102
SUPPLEMENTAL DISCLOSURES:		
Cash paid for interest	$ -	$ -
Cash paid for income taxes	$ -	$ -
NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Stock issued for debt	$ -	$ -
Debt discounted to capital	$ -	$ -

"The accompanying notes are an integral part of these financial statements"

NOTE 1 - ORGANIZATION AND OPERATIONS

Organization

Manzo Pharmaceuticals, Inc. (formerly - Fortune Oil & Gas Inc.) (the "*Company* ") was incorporated under the laws of the State of Nevada on January 24, 1980. The Company is an independent energy company engaged in the exploration, development, exploitation and production of oil and natural gas, in locations off the shore of Indonesia with operations focused mainly on the North Java Sea, Indonesia. In April of 2012 the company sold off its subsidiary corporations but maintained its intellectual properties, commission and license agreements, generating minimal but measurable revenue and owning substantial assets in the form of intellectual property as it operates to this day.

The Company was originally incorporated with an authorized capital of 25,000,000 shares of common stock with a par value of one cent ($0.001) per share. On 10/1/1999 the Company amended its articles of incorporation, changing its authorizing common stock to 50,000,000 shares at $0.001 par value. On 8/22/2002 the company amended its articles of incorporation once more to increase the authorized common shares to 100,000,000 with a par value of .001, and then again on 11/15/2010 to increase the authorized shares to 888,000,000 at a par value of.001. On 2/16/2012, the company amended its articles of incorporation to increase its number of authorized shares to 5,000,000,000 with a par value of .001, and on 4/25/2012, the company moved its state of incorporation to Wyoming.

On June 18, 2014 the company changed its name to Manzo Pharmaceuticals, Inc. and appointed Kenneth Manzo, an experienced chemist and licensed pharmacist, to the board of directors as the sole Officer and Director of the company. Mr. Manzo's appointment was done in conjunction with an agreement that laid out the acquisition of Manzo Pharmaceuticals LLC, an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The company also owns other products including a remedy for babies suffering from colic and/or digestive gas. The company sells this remedy online and plans to add many more to its product line in the near future. Fortune oil and gas will submit for a name change to Manzo pharmaceuticals and the business model will follow to target the multi-billion dollar alternative health sector.

The Company acquired 100% of Manzo Pharmaceutical LLC a Pennsylvania LLC in exchange for 2,000,000 shares of its Series "A; preferred stock on May 1 2014. This transaction was treated as a reverse merger for financial reporting purposes with Manzo Pharmaceutical LLC as the accounting acquirer. On September 17, 2014 the Company effectuated a reverse 10 for 1 stock split. All financial presented here have been adjusted to reflect this split.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant account policies of the Company is presented to assist in understanding the Company's financial statements. The financial statements and the notes are the representation of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles ("US GAAP") and have been consistently applied in the preparation of the financial statements.

Basis of Presentation

The Consolidated Financial Statements include the accounts of the Company and its majority-owned and wholly-owned subsidiaries. All significant intercompany account balances, transactions, profits and losses have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

For certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities.

Revenue Recognition

The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition for all its products sold whether sold to end users or through selected pharmacies. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the sales price is fixed or determinable, (iii) collectability is reasonably assured and (iv) goods have been shipped and/or services rendered..

Cash and Cash Equivalents

Cash comprise cash in hand and cash held on demand with banks. The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents are carried at cost, which approximates market value. Cash and cash equivalents comprise of the non-interest bearing checking accounts in US Dollars.

Accounts Receivables, Net

Accounts receivable represent amounts due from customers on product and other sales. These accounts receivable, which are reduced by an allowance for doubtful accounts, are recorded at the invoiced amount and do not bear interest. The Company evaluates the collectability of its accounts receivable based on a combination of factors, including whether sales were made pursuant to letters of credit. In cases where management is aware of circumstances that may impair a specific customer's ability to meet its financial obligations, management records a specific allowance against amounts due, and reduces the net recognized receivable to the amount the Company believes will be collected. For all other customers, the Company maintains an allowance that considers the total receivables outstanding, historical collection rates and economic trends. Accounts are written off when all efforts to collect have been exhausted.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and improvements are capitalized. As property and equipment are sold or retired, the applicable cost and accumulated depreciation are removed from the accounts and any resulting gain or loss thereon is recognized as operating expenses.

Depreciation is calculated using the straight-line method over the estimated useful lives or, in the case of leasehold improvements, the term of the related lease, including renewal periods, if shorter. Estimated useful lives are as follows:

Buildings	40 years
Equipment	5-15 years

The Company reviews property, plant and equipment and all amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability is based on estimated undiscounted cash flows. Measurement of the impairment loss, if any, is based on the difference between the carrying value and fair value.

Impairment of Long-Lived Assets and Amortizable Intangible Assets

The Company follows ASC 360-10, "Property, Plant, and Equipment," which established a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

Intangible Assets - Goodwill

The excess of the purchase price over net tangible and identifiable intangible assets of business acquired is carried as Goodwill on the balance sheet. Goodwill is not amortized, but instead is assessed for impairment at least annually and upon the occurrence of certain triggering events or substantive changes in circumstances that indicate that the fair value of goodwill may be impaired. Measurement of the impairment loss, if any, is based on the difference between the carrying value and fair value of reporting unit. The goodwill impairment test follows a two-step process. In the first step, the fair value of a reporting unit is compared to its carrying value. If the carrying value of a reporting unit exceeds its fair value, the second step of the impairment test is performed for purposes of measuring the impairment. In the second step, the fair value of the reporting unit is allocated to all of the assets and liabilities of the reporting unit to determine an implied goodwill value. If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of goodwill, an impairment loss will be recognized in an amount equal to that excess

Business segments

ASC 280, "Segment Reporting" requires use of the "management approach" model for segment reporting. The management approach model is based on the way a company's management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has one operating segments as of June 30, 2015 and 2014.

Fair Value Measurements

For certain financial instruments, including accounts receivable, accounts payable, interest payable, advances payable and notes payable, the carrying amounts approximate fair value due to their relatively short maturities.

On January 1, 2008, the Company adopted ASC 820-10, "Fair Value Measurements and Disclosures." ASC 820-10 defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The Company did not identify any non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC 815.

In February 2007, the FASB issued ASC 825-10 "Financial Instruments."ASC 825-10 permits entities to choose to measure many financial assets and financial liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings. ASC 825-10 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. The Company adopted ASC 825-10 on January 1, 2008. The Company chose not to elect the option to measure the fair value of eligible financial assets and liabilities.

Income Taxes

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Applicable interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of operations.

Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are

Special Purpose Entities

The Company does not have any off-balance sheet financing activities.

Net Income per Share

The Company computes net income (loss) per share in accordance with ASC 260-10, "Earnings Per Share." The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per share gives effect to all dilutive potential common shares outstanding during the period using the "as if converted" basis.

Common Stock

There is currently only one class of common stock. Each share common stock is entitled to one vote. The authorized number of common stock of the Company at March 31, 2016 was 1.900,000,000 shares with a nominal value per share of $0.001. Authorized shares that have been issued and fully paid amounted to 1,159,522,000 shares of common stocks.

Preferred Stock

The Company's Board of Directors has authorized the issuance of Series "A" Preferred stock of 4,000,000 with a nominal value per share of $0.001. 4,000,000 series "A" shares have been issued and each preferred share carries the voting rights of 1,000 common shares.

NOTE 3 - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financials properly reflect the change. The Company currently does not have any recent accounting pronouncements that they are studying and feel may be applicable.

NOTE 4- ACCOUNTS RECEIVABLE

The company currently has no receivables as all accounts are paid in full as of March 31, 2016.

NOTE 5 – NET INCOME PER SHARE

The following table sets forth the information used to compute basic and diluted net income per share attributable to MNZO for the three months ended March 31, 2016:

	3/31/2016	3/31/2015
Net Income (Loss)	$ (4,503)	$ (30,483)
Weighted-average common shares outstanding basic:		
Weighted-average common stock basic	1,159,522,000	464,522,000
Equivalents		
Stock options	-	-
Warrants	-	-
Convertible Notes	-	-
Weighted-average common shares outstanding- Diluted	1,159,522,000	464,522,000

NOTE 6- ACQUISITIONS AND INTANGIBLES

During the fiscal year ended December 31, 2012, the Company acquired Fortune Oil & Gas Inc.. The acquisitions were also accounted for as business purchases and recorded at the estimated fair values of the net tangible and identifiable intangible assets acquired.

	3/31/2016	**12/31/2015**
Trademarks	$ 65,000	$ 65,000
Software	5,000	5,000
Intangible Assets, Net	70,000	70,000
Goodwill	$ 110,100	$ 110,100
Goodwill, Net	$ 110,100	$ 110,100

NOTE 7 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Currently, the Company has limited operating history and has incurred continuing operating losses, and as of March 31, 2016 the Company had insufficient working capital on hand. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company's capital requirements will depend on many factors including the success of the Company's development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There is no assurance that such financing will be available in the future. The conditions described above raise substantial doubt about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Commitments:

None.

Contingencies:

None.

NOTE 9 - DISCONTINUED OPERATIONS

On or around April of 2012, the company was divested of its mining operations, but continued operating as a licensing company maintaining its intellectual property and attempting to license it. Currently, management is preparing to acquire Manzo pharmaceuticals, which will change the company direction to include the sale of alternative health aids.

NOTE 10- RELATED PARTY TRANSACTIONS

During the past three months ended March 31, 2016, the Company had funds of $8,405 lent to the company from related parties. These loans are due on demand and have a zero percent interest rate. The Company currently also pays direct business expenses for space used in the CEO's home. These include phone internet, etc. and are done on a month to month basis with no commitments.

NOTE 11- INCOME TAXES

Deferred income tax assets and liabilities are computed annually for differences between financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

The effective tax rate on the net loss before income taxes differs from the U.S. statutory rate as follows:

	3/30/2016
U.S statutory rate	34.00%
Less valuation allowance	(34.00)%
Effective tax rate	0.00%

The significant components of deferred tax assets and liabilities are as follows:

		3/31/2016
Deferred tax assets		
Net operating losses	$	(4,503)
Deferred tax liability		
Net deferred tax assets		(1,531)
Less valuation allowance		1,531
Deferred tax asset - net valuation allowance	$	0

On an interim basis, the Company has a net operating loss carryover of approximately $4,503 available to offset future income for income tax reporting purposes, which will expire in various years through 2032, if not previously utilized. However, the Company's ability to use the carryover net operating loss may be substantially limited or eliminated pursuant to Internal Revenue Code Section 382. The Company adopted the provisions of ASC 740-10-50, formerly FIN 48, and "Accounting for Uncertainty in Income Taxes". The Company had no material unrecognized income tax assets or liabilities as of March 31, 2016.

The Company's policy regarding income tax interest and penalties is to expense those items as general and administrative expense but to identify them for tax purposes. During the six months ended March 31, 2016, there was no income tax, or related interest and penalty items in the income statement, or liabilities on the balance sheet. The Company files income tax returns in the U.S. federal jurisdiction and Nevada state jurisdiction. We are not currently involved in any income tax examinations.

END OF NOTES TO FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED March 31, 2016

6) Describe the Issuer's Business, Products and Services

A. On June 18, 2014 the company changed its name to Manzo Pharmaceuticals, Inc. and appointed Kenneth Manzo, an experienced chemist and licensed pharmacist, to the board of directors as the sole Officer and Director of the company. Mr. Manzo's appointment was done in conjunction with an agreement that laid out the acquisition of Manzo Pharmaceuticals LLC, an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The company also owns other products including a remedy for babies suffering from colic and/or digestive gas. The company sells this remedy online and plans to add many more to its product line in the near future. Fortune oil and gas will submit for a name change to Manzo pharmaceuticals and the business model will follow to target the multi-billion dollar alternative health sector.

B. The company was originally incorporated in 1980

C. The company's SIC code as of 3/31/2016 is 2833 - Medicinal and botanicals

D. Manzo Pharmaceuticals, Inc.'s fiscal year ends on December 31st.

E. The Company's primary product is Dietary Supplements, pro-biotics and natural remedies

7) Describe the Issuer's Facilities

The company currently has facilities in Milford, PA, which are part of property owned by the CEO, and costs the company nothing at the moment. As operations ramp up the company will look for larger facilities.

8) Officers, Directors, and Control Persons

A. As of the date of this information statement, the board consist of Kenneth Manzo, Jason Randolph, and Thomas Morton.

B. They have NO disciplinary history whatsoever, and has never had a criminal conviction, entry of a judgment or decree by a court of any jurisdiction that limited his involvement with any type of business, securities, commodities, or banking activities. Furthermore they have never had a finding or judgment against them nor any order by self-regulatory organizations of any kind.

C. As of the date of this information statement the only individual or entity owning more than 10% of the company's common or preferred securities is as follows:

Kenneth Manzo, President/CEO/Director
PO Box 107,
Milford, PA 18337
Ownership: 2,000,000 Shares of Preferred Series A Shares

9) Third Party Providers

Legal Counsel
Name: Kaleem Sikandar, ESQ
Firm: THE LAW OFFICE OF KALEEM SIKANDAR
Address 1: 204B East Main Street
Address 2: Port Jefferson, NY 11777
Email: Kaleem.Sikandar@gmail.com

10) Issuer Certification

I, Kenneth Manzo certify that:

1. I have reviewed this Quarterly disclosure statement for the three months ended March 31, 2016 of Manzo Pharmaceuticals, Inc. Symbol: MNZO;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

5/19/16
[Date]

/S/ Kenneth Manzo [CEO's Signature]

/S/ Kenneth Manzo [CFO's Signature]